As of June 12, 2025, Protara Therapeutics Inc (TARA) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Protara Therapeutics Inc's Gross Margin to Peers
To better understand Protara Therapeutics Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Protara Therapeutics Inc (TARA) | 7775.20% |
| Synlogic Inc (SYBX) | 7775.20% |
| Axcella Health Inc (AXLA) | 7775.20% |
| Medicenna Therapeutics Corp (MDNA.TO) | 7775.20% |
| Biomx Inc (PHGE) | 7775.20% |
| Aptinyx Inc (APTX) | 7775.20% |
Compared to its competitors, Protara Therapeutics Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.